Moore RD - Search Results

1

Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV.

Kim HN, Nance RM, Lo Re V 3rd, Silverberg MJ, Franco R, Sterling TR, Cachay ER, Horberg MA, Althoff KN, Justice AC, Moore RD, Klein M, Crane HM, Delaney JA, Kitahata MM. Kim HN, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2022 Apr 1;89(4):396-404. doi: 10.1097/QAI.0000000000002886. J Acquir Immune Defic Syndr. 2022. PMID: 35202048 Free PMC article.

2

Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity.

Sterling TR, Chaisson RE, Moore RD. Sterling TR, et al. Among authors: moore rd. Clin Infect Dis. 2003 Mar 15;36(6):812-5. doi: 10.1086/367934. Epub 2003 Feb 27. Clin Infect Dis. 2003. PMID: 12627368

3

The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons.

Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. Mehta SH, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):577-84. doi: 10.1097/00126334-200308150-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12902801

4

Hospitalization rates differ by hepatitis C satus in an urban HIV cohort.

Gebo KA, Diener-West M, Moore RD. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):165-73. doi: 10.1097/00126334-200310010-00006. J Acquir Immune Defic Syndr. 2003. PMID: 14526205

5

Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.

Sterling TR, Chaisson RE, Keruly J, Moore RD. Sterling TR, et al. Among authors: moore rd. J Infect Dis. 2003 Dec 1;188(11):1659-65. doi: 10.1086/379741. Epub 2003 Nov 14. J Infect Dis. 2003. PMID: 14639536

6

Differences in HIV disease progression by injecting drug use in HIV-infected persons in care.

Moore RD, Keruly JC, Chaisson RE. Moore RD, et al. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):46-51. doi: 10.1097/00126334-200401010-00006. J Acquir Immune Defic Syndr. 2004. PMID: 14707791

7

Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.

Gebo KA, Gallant JE, Keruly JC, Moore RD. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1028-33. doi: 10.1097/00126334-200408150-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15247555

8

Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, Moore RD, Hellinger J, Keiser P, Rubin HR, Crane L, Hellinger FJ, Mathews WC; HIV Research Network. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):96-103. doi: 10.1097/00126334-200501010-00017. J Acquir Immune Defic Syndr. 2005. PMID: 15608532

9

The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection.

Mehta SH, Thomas DL, Torbenson M, Brinkley S, Mirel L, Chaisson RE, Moore RD, Sulkowski MS. Mehta SH, et al. Among authors: moore rd. Hepatology. 2005 Jan;41(1):123-31. doi: 10.1002/hep.20541. Hepatology. 2005. PMID: 15619237

10

The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era.

Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):169-74. doi: 10.1097/01.qai.0000178408.62675.b0. J Acquir Immune Defic Syndr. 2005. PMID: 16186734

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

904 results

Search Page